Privileged Structures and Polypharmacology within and between Protein Families

[Image: see text] Polypharmacology is often a key contributor to the efficacy of a drug, but is also a potential risk. We investigated two hits discovered via a cell-based phenotypic screen, the CDK9 inhibitor CCT250006 (1) and the pirin ligand CCT245232 (2), to establish methodology to elucidate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyers, Joshua, Chessum, Nicola E. A., Ali, Salyha, Mok, N. Yi, Wilding, Birgit, Pasqua, A. Elisa, Rowlands, Martin, Tucker, Michael J., Evans, Lindsay E., Rye, Carl S., O’Fee, Lisa, Le Bihan, Yann-Vaï, Burke, Rosemary, Carter, Michael, Workman, Paul, Blagg, Julian, Brown, Nathan, van Montfort, Rob L. M., Jones, Keith, Cheeseman, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295861/
https://www.ncbi.nlm.nih.gov/pubmed/30613326
http://dx.doi.org/10.1021/acsmedchemlett.8b00364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295861/
https://www.ncbi.nlm.nih.gov/pubmed/30613326
http://dx.doi.org/10.1021/acsmedchemlett.8b00364

Ejemplares similares